A2AR antagonist treatment for multiple sclerosis: Current progress and future prospects

Chenxing Qi, Yijia Feng, Yiwei Jiang, Wangchao Chen, Serhii Vakal, Jiang Fan Chen, Wu Zheng*

*Tämän työn vastaava kirjoittaja

Tutkimustuotos: Artikkeli kirjassa/raportissa/konferenssijulkaisussaLukuTieteellinenvertaisarvioitu

Abstrakti

Emerging evidence suggests that both selective and non-selective Adenosine A2A receptor (A2AR) antagonists could effectively protect mice from experimental autoimmune encephalomyelitis (EAE), which is the most commonly used animal model for multiple sclerosis (MS) research. Meanwhile, the recent FDA approval of Nourianz® (istradefylline) in 2019 as an add-on treatment to levodopa in Parkinson's disease (PD) with “OFF” episodes, along with its proven clinical safety, has prompted us to explore the potential of A2AR antagonists in treating multiple sclerosis (MS) through clinical trials. However, despite promising findings in experimental autoimmune encephalomyelitis (EAE), the complex and contradictory role of A2AR signaling in EAE pathology has raised concerns about the feasibility of using A2AR antagonists as a therapeutic approach for MS. This review addresses the potential effect of A2AR antagonists on EAE/MS in both the peripheral immune system (PIS) and the central nervous system (CNS). In brief, A2AR antagonists had a moderate effect on the proliferation and inflammatory response, while exhibiting a potent anti-inflammatory effect in the CNS through their impact on microglia, astrocytes, and the endothelial cells/epithelium of the blood–brain barrier. Consequently, A2AR signaling remains an essential immunomodulator in EAE/MS, suggesting that A2AR antagonists hold promise as a drug class for treating MS.

AlkuperäiskieliEnglanti
OtsikkoAdenosine A Receptor Antagonists
ToimittajatJiang-Fan Chen, Akihisa Mori
KustantajaApple Academic Press Inc.
Sivut185-223
Vuosikerta170
ISBN (painettu)9780443186677
DOI - pysyväislinkit
TilaJulkaistu - 2023
OKM-julkaisutyyppiA3 Kirjan osa tai toinen tutkimuskirja

Julkaisusarja

NimiInternational Review of Neurobiology
Vuosikerta170
ISSN (painettu)0074-7742
ISSN (elektroninen)2162-5514

Sormenjälki

Sukella tutkimusaiheisiin 'A2AR antagonist treatment for multiple sclerosis: Current progress and future prospects'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Viittausmuodot